EXAS Stock Analysis & Forecast (2026)

Exact Sciences Corp Healthcare Diagnostics & Research
$104.91
Current Price
51%
Hold
View Plans
Data refreshed: April 22, 2026

Key Financial Metrics

Market Cap
$20.03B
P/E Forward
55.2x
Revenue Growth
23.1%
Gross Margin
69.7%
Net Margin
-6.4%
Return on Equity
-8.7%
Debt/Equity
1.06

AI Analysis Summary

Exact Sciences Corp (EXAS) is a Healthcare company in the Diagnostics & Research industry with a 51% Hold Score. Key strengths include Revenue Growth (23.1%), Gross Margin (69.7%). Areas to watch: Net Margin (-6.4%), Return on Equity (-8.7%). Our AI evaluates 8 fundamental categories including revenue growth, margin quality, balance sheet strength, cash flow generation, return on capital, and valuation metrics.

Revenue Growth: Strong Gross Margin: Excellent Net Margin: Negative Return on Equity: Negative Debt/Equity: High Risk

This analysis is generated by StrongBuyAnalytics AI using publicly available financial data from SEC filings, earnings reports, and market feeds. It is not personalized investment advice. See our methodology and disclaimer.

EXAS Fundamental Analysis Report
PDF Report Preview
51%
Strong Buy Score
  • 8 Fundamental Categories Analyzed
  • Revenue & Growth Trends
  • Margin & Profitability Analysis
  • Balance Sheet Strength
  • Cash Flow Quality
  • Valuation Assessment
  • AI-Powered Investment Insights
Get Your Free EXAS Report

How It Works: AI Stock Analysis in 60 Seconds

See how our AI analyzes EXAS fundamentals to generate buy/sell signals and Strong Buy Scores.

Why EXAS Has a 51% Score

Our AI evaluates Exact Sciences Corp's fundamentals across multiple dimensions. Here is what is driving the current Hold rating:

Recent Catalysts for EXAS

Key developments and data points that may impact Exact Sciences Corp's trajectory:

Analyst consensus recommendation: Hold.
Institutional ownership at 86.5% — strong smart-money backing.

EXAS vs. Peers

How Exact Sciences Corp stacks up against comparable Healthcare companies on key metrics:

Ticker Price Market Cap P/E Rev Growth Net Margin ROE
EXAS $104.91 $20.03B 23.1% -6.4% -8.7%
JNJ $226.16 $545.02B 20.5x 9.9% 21.8%
UNH $346.01 $314.06B 26.2x 12.3% 2.7% 12.5%
PFE $27.31 $155.35B 20.1x -1.2% 12.4% 8.9%
MRK $112.56 $278.29B 15.5x 5.0% 28.1% 36.9%

Main Risks for EXAS Investors

Every investment carries risk. Here are the specific risk factors our analysis identified for Exact Sciences Corp:

Net Margin (-6.4%)
Return on Equity (-8.7%)
Debt/Equity (1.06)
High beta of 1.44 means the stock is 44% more volatile than the market — expect larger drawdowns in corrections.
Short interest is elevated with a 3.2-day cover ratio, indicating bearish bets against the stock.
High leverage amplifies downside risk if revenue softens or interest rates rise.

Generate the full PDF report for a detailed risk-reward framework and bear-case scenarios.

EXAS Balance Sheet & Cash Flow

A snapshot of Exact Sciences Corp's financial health based on the most recent filings:

Total Cash
$964.71M
Total Debt
$2.53B
Current Ratio
2.43
FCF Yield
1.4%
EBITDA
$71.46M
Operating Margin
-9.3%

Data sourced from the latest SEC filings. Generate the full PDF report for detailed balance sheet and cash flow commentary.

EXAS Valuation Snapshot

Forward P/E
55.2x
Price / Book
8.3x
High intangible value
Analyst Target (Mean)
$106.30
Range: $105 – $118
52-Week Price Range — EXAS is trading at 100% of its range
$38.81 (52W Low) $104.98 (52W High)

Is EXAS a Buy Right Now?

Based on our AI-powered fundamental analysis, EXAS has a Strong Buy Score of 51%, earning a "Hold" rating. This score synthesizes 8 key financial metrics to provide an objective investment signal.

Moderate Buy Signal

Exact Sciences Corp shows mixed fundamentals with some strengths and areas to monitor. Positives include Revenue Growth (23.1%). Watch for Net Margin (-6.4%).

EXAS AI Buy & Sell Signals Explained

Our AI analyzes Exact Sciences Corp's financial statements to generate buy/sell signals based on quantitative metrics, not market sentiment or news headlines. Here's what drives the 51% score:

  • Revenue Growth: 23.1% year-over-year (above average)
  • Gross Margin: 69.7% (strong pricing power)
  • Net Margin: -6.4% (unprofitable)
  • Return on Equity: -8.7% (negative returns)

Generate the full PDF report for complete category-by-category scoring and AI-powered investment recommendations.

Key Support / Demand Zones

Technical traders can view real-time demand and supply zones for EXAS on our Demand Zones page. These zones identify key price levels where institutional buying or selling has historically occurred.

With EXAS currently trading at $104.91, our system monitors proximity to these critical levels and can alert you when the stock approaches support or resistance zones.

Subscribe to demand zone alerts to receive real-time notifications when EXAS reaches key technical levels.

Earnings & Revenue Outlook

Exact Sciences Corp operates in the Healthcare sector, specifically in Diagnostics & Research. Understanding earnings trends is crucial for forecasting EXAS's trajectory.

Current revenue growth of 23.1% significantly outpaces the average company. This strong growth trajectory supports a higher valuation multiple.

Visit our Earnings Calendar to track upcoming EXAS earnings dates and historical beat/miss patterns. Sign up for earnings alerts to get notified before announcements.

EXAS Stock Forecast (Next 3–12 Months)

Our AI projects EXAS's trajectory based on current fundamentals and historical patterns. With a 51% Strong Buy Score, here's what the data suggests:

Mixed Outlook: Exact Sciences Corp shows moderate fundamental strength. Revenue growth at 23.1% is positive but warrants monitoring. The stock may trade sideways or experience modest gains depending on execution and market conditions.

For a complete 12-month price forecast with specific bull/bear scenarios, generate the full PDF report.

Valuation Metrics (P/E, Growth, Margins)

Understanding valuation is critical for determining if EXAS is fairly priced. Here's the current snapshot:

  • Market Capitalization: $20.03B
  • Forward P/E: 55.2x (based on analyst estimates)
  • Debt/Equity: 1.06 (higher leverage)

Our AI weighs these metrics against growth rates and margin quality to determine if EXAS offers compelling risk-adjusted returns at current prices.

Bull Case for EXAS

Here's why investors are bullish on Exact Sciences Corp:

  • Revenue Growth (23.1%)
  • Gross Margin (69.7%)

While these positives exist, investors should weigh them against the risks outlined in the bear case below.

Bear Case & Risks for EXAS

Every investment carries risk. Here are potential concerns for EXAS investors:

  • Net Margin (-6.4%)
  • Return on Equity (-8.7%)
  • Debt/Equity (1.06)

The full PDF report includes a detailed bear case analysis with specific risk ratings for each category.

Summary / 12-Month Outlook

EXAS Summary: Exact Sciences Corp earns a 51% Hold Score based on AI analysis of fundamental data. Trading at $104.91 with a $20.03B market cap, the stock presents a balanced risk/reward profile for the coming year.

Bull Case: Revenue Growth (23.1%), Gross Margin (69.7%)

Watch: Net Margin (-6.4%), Return on Equity (-8.7%)

For the complete analysis with specific price considerations, growth projections, and AI-powered buy/hold/sell recommendations, generate your free EXAS PDF report.

Learn More About Stock Analysis

Deepen your understanding of the concepts used in this EXAS analysis:

Fundamental Analysis Guide

Learn how to evaluate stocks using financial statements and key metrics.

Understanding P/E Ratio

What P/E ratio tells you about a stock's valuation and growth expectations.

Return on Equity (ROE)

Why ROE matters for stock selection and how to interpret it.

Stock Valuation Methods

Compare DCF, P/E, and other approaches to value stocks like EXAS.

What Are Demand Zones?

Find key support and resistance levels for EXAS and other stocks.

How to Read Earnings Reports

Understand earnings per share, revenue surprises, and guidance.

Related Tools for EXAS

Demand Zone Analyzer EXAS Live Chart EXAS SEC Filing News Earnings Calendar Institutional Ownership Sector Scanner Average Down Calculator

EXAS SEC Filing News

Latest SEC filings for EXAS explained in plain English — insider buys/sells (Form 4), proposed sales (Form 144), material events (8-K), and quarterly & annual reports.

Loading recent SEC filings…
View all EXAS SEC Filing News →

Frequently Asked Questions about EXAS

Is EXAS a good buy right now?
EXAS currently has a Strong Buy Score of 51% (Hold). EXAS shows moderate buy signals. The stock has mixed fundamentals worth reviewing in detail. Generate a free PDF report for specific buy/hold/sell recommendations.
What is the EXAS stock forecast for 2026?
Our AI forecasts EXAS based on current fundamentals: revenue growth of 23.1%, net margin of -6.4%. The 51% Strong Buy Score reflects our outlook combining growth trajectory, margin quality, and valuation. See the full 12-month projection in your PDF report.
What are key support and resistance levels for EXAS?
View real-time EXAS demand zones (support) and supply zones (resistance) on our Demand Zones page. With EXAS currently at $104.91, you can see how close the stock is to key technical levels. Subscribe to get alerts when EXAS approaches these zones.
How do EXAS fundamentals compare to peers?
Exact Sciences Corp operates in the Healthcare sector. Key metrics for peer comparison: Gross margin 69.7%, ROE -8.7%, Debt/Equity 1.06. The 51% Strong Buy Score factors in how these metrics stack up against industry averages. Data is refreshed daily.
Is the EXAS analysis PDF report free?
Yes! Your first EXAS fundamental analysis report is completely free with no credit card required. The PDF includes the full Strong Buy Score breakdown, all 8 fundamental categories analyzed, AI-powered insights, and specific investment recommendations. Additional reports are available through our subscription plans starting at $24/month.
What is Exact Sciences Corp's market cap and P/E ratio?
Exact Sciences Corp (EXAS) has a market cap of $20.03B (forward P/E: 55.2x). These valuation metrics are key factors in our Strong Buy Score calculation. See all metrics in the PDF report for comprehensive valuation analysis.

This EXAS analysis is for educational and informational purposes only and does not constitute financial advice. All data is sourced from public filings and market feeds. Past performance does not guarantee future results. Read our full disclaimer.